• April 12, 2022

NeuroSense initiates subject dosing in PK study of ALS asset

Read More

• April 6, 2022

NeuroSense Therapeutics – Study of New Drug to Treat ALS

Read More

• March 31, 2022

Spirit of ALS Patient Drives NeuroSense Mission to Bring PrimeC to Market

Read More

• March 21, 2022

NeuroSense Shares Surge Over 400% As FDA Clears Initiating PK Study Of PrimeC

Read More

• December 13, 2021

NeuroSense initiates subject dosing in pharmacokinetics study of ALS asset

Read More

• December 8, 2021

NeuroSense Therapeutics Announces Pricing of $12 Million Initial Public Offering

Read More

• March 3, 2021

Neurosense Completes Successful Phase IIA And Receives Patent Allowance

Read More

• January 12, 2021

Neurosense Granted European Orphan Drug Designation

Read More

• January 7, 2021

Neurosense’s Origins, Current Status And Plans Forward

Read More

• December 10, 2020

Neurosense Presents At ALS/MND Symposium

Read More

• November 18, 2020

Continuation Of Positive Trends In Als Clinical Trial

Read More

• September 30, 2020

Neurosense’s Clinical Trial Interim Results Webinar

Read More

• September 24, 2020

Introducing The Women Behind Neurosense

Read More

• September 9, 2020

Encouraging Interim Results Of Neurosense’s Clinical Study

Read More

• February 12, 2020

Clinical Studies Initiation And Orphan Drug Designation

Read More

• March 25, 2019

Meet Our Investors

Read More

• February 10, 2019

Read Neurosense’s Story

Read More

• January 3, 2019

Zebrafish Assist In The Battle Against ALS

Read More